CLINICAL TRIALS PROFILE FOR ADENOSCAN

All Clinical Trials for Adenoscan

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00208299 ↗	ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)	Completed	Astellas Pharma US, Inc.	Phase 3	2003-10-01	Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. The investigational drug, regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist, the receptor responsible for coronary vasodilation, and is being studied for potential use as a pharmacologic stress agent in myocardial perfusion imaging (MPI) studies. This study will compare the safety and efficacy of regadenoson to that of Adenoscan in detecting reversible myocardial perfusion defects.
NCT00208299 ↗	ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)	Completed	Gilead Sciences	Phase 3	2003-10-01	Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. The investigational drug, regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist, the receptor responsible for coronary vasodilation, and is being studied for potential use as a pharmacologic stress agent in myocardial perfusion imaging (MPI) studies. This study will compare the safety and efficacy of regadenoson to that of Adenoscan in detecting reversible myocardial perfusion defects.
NCT00208312 ↗	ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)	Completed	Astellas Pharma US, Inc.	Phase 3	2004-04-01	Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. The investigational drug, regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist, the receptor responsible for coronary vasodilation, and is being studied for potential use as a pharmacologic stress agent in myocardial perfusion imaging (MPI) studies. This study will compare the safety and efficacy of regadenoson to that of Adenoscan in detecting reversible myocardial perfusion defects.
NCT00208312 ↗	ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)	Completed	Gilead Sciences	Phase 3	2004-04-01	Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. The investigational drug, regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist, the receptor responsible for coronary vasodilation, and is being studied for potential use as a pharmacologic stress agent in myocardial perfusion imaging (MPI) studies. This study will compare the safety and efficacy of regadenoson to that of Adenoscan in detecting reversible myocardial perfusion defects.
NCT00859833 ↗	Effects of Body Mass Index on the Hyperemic Response to Regadenoson	Completed	Astellas Pharma Inc	N/A	2009-02-01	We will test the hypothesis that a single dose of Regadenoson will produce equivalent degrees of coronary hyperemia in patients of widely different body size. This will be a prospective, open-label, comparative trial using MRI to measure myocardial perfusion reserve (ratio of myocardial blood flow with vasodilator to myocardial blood flow at rest) during sequential administration of the coronary vasodilators adenosine and regadenoson. Non-invasive MRI measurements of resting myocardial blood flow, and sequential measurements of blood flow during adenosine infusion (weight adjusted dosing) and then blood flow during regadenoson infusion (single, fixed dose. Blood flow measurements will be obtained sequentially and in the same sequence in each subject during a two hour MRI exam. 32 subjects will be recruited for this study. The first 2 will be for testing of the protocol. Inclusion criteria: 2 subjects for initial protocol evaluation, then 30 subjects with body mass index (BMI) between 18 and 40. Exclusions are pregnancy, renal dysfunction and claustrophobia.

Clinical Trial Conditions for Adenoscan

Condition Name

Condition Name for Adenoscan
Intervention	Trials
Coronary Artery Disease	6
MRI Scans	2
Myocardial Ischemia	1
Obesity	1

Condition MeSH

Condition MeSH for Adenoscan
Intervention	Trials
Myocardial Ischemia	7
Coronary Artery Disease	7
Coronary Disease	6
Heart Failure	1

Clinical Trial Locations for Adenoscan

Trials by Country

Trials by Country for Adenoscan
Location	Trials
United States	66
Brazil	6
Netherlands	3
Argentina	3
Belgium	1

Trials by US State

Trials by US State for Adenoscan
Location	Trials
Utah	5
California	4
New York	3
Minnesota	3
Louisiana	3

Clinical Trial Progress for Adenoscan

Clinical Trial Phase

Clinical Trial Phase for Adenoscan
Clinical Trial Phase	Trials
Phase 3	4
N/A	5
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for Adenoscan
Clinical Trial Phase	Trials
Completed	5
Recruiting	2
Terminated	2

Clinical Trial Sponsors for Adenoscan

Sponsor Name

Sponsor Name for Adenoscan
Sponsor	Trials
University of Utah	3
Astellas Pharma US, Inc.	2
Gilead Sciences	2

Sponsor Type

Sponsor Type for Adenoscan
Sponsor	Trials
Industry	11
Other	6
NIH	1

Adenoscan: Clinical Trials, Market Analysis, and Projections

Introduction to Adenoscan

Adenoscan, also known as adenosine, is a medication used primarily for its vasodilatory properties, particularly in the diagnosis and treatment of certain heart conditions. Here, we will delve into the current state of clinical trials, market analysis, and future projections for Adenoscan.

Clinical Trials Update

Current Trials and Recent Developments

While Adenoscan itself is an established drug, research and development in the broader field of adenosine and its antagonists continue to evolve. Here are some key updates:

• Adenosine Antagonists: Companies like Corvus Pharmaceuticals, Arcus Biosciences, and Palobiofarm are actively involved in clinical trials for adenosine antagonists, which are being explored for various therapeutic applications, including oncology, neurodegenerative diseases, and cardiovascular disorders. For instance, Corvus Pharmaceuticals has reported promising results from its Phase 1b/2 trial of ciforadenant, an adenosine antagonist, in combination with other therapies for metastatic renal cell cancer[4].

• Combination Therapies: The focus on combination therapies is significant. For example, the combination of adenosine antagonists with immunotherapies like anti-PD-1 and anti-CTLA-4 has shown potential in overcoming resistance to immunotherapy in certain cancers[4].

Ongoing and Future Trials

• Phase II and III Trials: Several adenosine antagonists are in advanced stages of clinical trials. Palobiofarm's PBF-680, for instance, has shown positive top-line results in a Phase II trial for moderate-to-severe COPD[4].

• Expanding Indications: The pipeline for adenosine antagonists includes drugs being evaluated for a range of conditions, from cancer to COPD and neurodegenerative diseases. This diversification indicates a robust future for adenosine-related therapies[4].

Market Analysis

Market Size and Growth

The adenosine market, which includes Adenoscan and other adenosine-related products, is experiencing steady growth driven by several factors:

• Increasing Research: The market is driven by increasing research in biochemistry, pharmaceuticals, and cellular biology. The demand for adenosine in these fields is expected to boost the market size[2].

• Therapeutic Applications: The expanding therapeutic applications of adenosine, including cancer, neurological disorders, and heart diseases, are key drivers. The market size for adenosine cyclophosphate, for example, is projected to reach USD 105.2 million by 2030, growing at a CAGR of 6.1% from 2024 to 2030[2].

• Geographical Trends: The market is geographically diverse, with North America and Asia-Pacific regions showing significant growth due to increased investments in research and development. Regulatory frameworks and regional economic conditions also play a crucial role in market growth[2][5].

Competitive Landscape

The competitive landscape for adenosine and its antagonists is dynamic, with several key players:

• Major Players: Companies like Corvus Pharmaceuticals, Arcus Biosciences, Portage Biotech, and Palobiofarm are leading the development of new adenosine antagonists. These companies are investing heavily in R&D to advance their pipeline assets[4].

• Market Share: The market share is distributed among these key players, with smaller players also contributing to the overall market growth. The competitive analysis includes company profiles, SWOT analysis, and market share data[5].

Market Projections

Future Growth Potential

The future of the adenosine market looks promising due to several factors:

• Technological Advancements: Innovations in drug delivery systems and formulation are expected to enhance the efficacy and safety profiles of adenosine-related therapies, driving market growth[2].

• Expanding Applications: The development of novel applications, particularly in the fields of oncology and neurodegenerative diseases, will continue to expand the market. Combination therapies and targeted treatments are expected to improve patient outcomes, further boosting market growth[3][4].

• Regulatory Approvals: Advancements through clinical trials and regulatory approvals will bolster market credibility and expand demand. Positive outcomes from ongoing trials, such as those for ciforadenant and PBF-680, are expected to contribute significantly to market growth[4].

Regional Trends

• Emerging Markets: The market is expected to see significant growth in emerging economies due to rising disposable incomes and urbanization. Sustainability trends and legislative backing are also expected to drive market growth in these regions[2].

• North America and Asia-Pacific: These regions are anticipated to continue their strong growth trajectory due to increased investments in biotechnology and life sciences research[2][5].

Key Takeaways

• Clinical Trials: Ongoing clinical trials for adenosine antagonists show promising results, particularly in combination therapies for cancer and other diseases.
• Market Growth: The adenosine market is projected to grow at a CAGR of 6.1% from 2024 to 2030, driven by increasing research, therapeutic applications, and technological advancements.
• Competitive Landscape: Key players like Corvus Pharmaceuticals and Arcus Biosciences are driving innovation and market growth.
• Future Potential: Expanding applications, regulatory approvals, and technological advancements will continue to drive the market forward.

FAQs

What are the primary uses of Adenoscan?

Adenoscan, or adenosine, is primarily used for its vasodilatory properties, especially in the diagnosis and treatment of heart conditions such as supraventricular tachycardia.

Which companies are leading the development of adenosine antagonists?

Companies like Corvus Pharmaceuticals, Arcus Biosciences, Portage Biotech, and Palobiofarm are leading the development of new adenosine antagonists.

What is the projected market size for adenosine cyclophosphate by 2030?

The market size for adenosine cyclophosphate is projected to reach USD 105.2 million by 2030, growing at a CAGR of 6.1% from 2024 to 2030[2].

What are the key drivers of the adenosine market?

The key drivers include increasing research in biochemistry and pharmaceuticals, expanding therapeutic applications, and technological advancements in drug delivery systems.

Which regions are expected to see significant growth in the adenosine market?

North America and Asia-Pacific regions are expected to see significant growth due to increased investments in research and development and favorable regulatory frameworks[2][5].

Sources

1. Corvus Pharmaceuticals Provides Business Update and Reports Financial Results for the First Quarter Ended March 31, 2024. Corvus Pharmaceuticals.
2. Adenosine Cyclophosphate Market Key Drivers and Forecast 2025-2032. Verified Market Reports.
3. Gastric Cancer Drugs Market Size to Reach USD 12.5 Billion by 2032. BioSpace.
4. Adenosine Antagonists Clinical Trial Pipeline Analysis: 10+ Key Companies Shaping the Future of Adenosine Antagonists Therapeutics. GlobeNewswire.
5. Worldwide Adenosine Industry to 2025 - Key Drivers, Restraints, Opportunities and Threats. Business Wire.